

A white handheld medical device, the iLUX, is shown against a dark blue circular background. The device has a digital display screen showing 'eyelid 41°C', 'melt time 08 sec', and 'LED 82 sec'. It features a large, curved handle and a small, white, curved applicator tip at the end of the device.

iLUX®

TAKE CONTROL AND TREAT MGD WITH CONFIDENCE


For personalized, real dry eye relief,
the iLUX® device, with its advanced Smart Tip Patient Interface,
gives you results you can see.

Alcon A Novartis
Division

OVER 30 MILLION PEOPLE IN THE U.S. SUFFER FROM DRY EYE.¹

86% OF DRY EYE PATIENTS HAVE
SIGNS OF MEIBOMIAN GLAND
DYSFUNCTION (MGD).²

MGD is a chronic disease with symptoms of dryness, irritation, itchiness, blurred vision and watery eyes, and to date, has no permanent cure.



Did you know?

Patients with **severe** dry eye have a lost utility comparable to patients with **moderate to severe** angina.^{3,*}

THE DRY EYE OPPORTUNITY

In-office procedures are becoming the fastest growing segment in dry eye treatment — with nearly **8 out of 10 doctors** considering dry eye treatment as an opportunity to grow their practice.⁴

ENTERING PATIENTS INTO A SYSTEM OF DRY EYE CARE

As patients often ignore symptoms, improving dry eye care starts with a diagnosis. Ask your patients if they use artificial tears and how often. **The earlier you start the dry eye conversation, the sooner you can make an impact.**



ALCON'S COMMITMENT

We strive to be the best in helping you provide outstanding care to your patients.

Alcon is the global leader in eyecare excellence, improving vision through innovation since 1945. We're partnering with you to provide outstanding products that help your patients see, look and feel their best.

*Utility (patient preference for health outcomes) was measured using the time trade-off (TTO) method, in which patients were offered 2 choices: 1) living x years (life expectancy for the person with this disease) or 2) being in perfect health for fewer years (y < x) followed by death.

ALCON INTRODUCES iLUX[®]

iLUX[®] is an MGD treatment device that incorporates the innovative Smart Tip Patient Interface and targets blocked meibomian glands that require expression.

Indication: The iLUX[®] Device is indicated for the application of localized heat and pressure therapy in adult patients with chronic disease of the eyelids, including Meibomian Gland Dysfunction (MGD), also known as evaporative dry eye.

iLUX[®] gives you control to confidently deliver outstanding MGD treatment:

- Visualize treatment zones
- Personalize the treatment to respond to patient feedback
- Take control — treat your patient in your office
- Feel confident that the treatment can deliver relief from MGD symptoms

Smart Tip Patient Interface brings advanced technology to the site of treatment:

- Precision sensors continually monitor eyelid temperatures to maintain therapeutic heat levels
- Heat and pressure levels can be personalized to your patient's needs
- Consistently deliver an effective treatment with a unique Method of Action
- Eyelid pads are covered with a soft, biocompatible silicone material for patient comfort



EFFECTIVE AND INTUITIVE

iLUX[®] can be used by physicians and practice technicians.

SEE IT

View the blocked meibomian glands through the magnifying lens.

HEAT IT

Press the button to apply light-based heating to the treatment area.

TREAT IT

Have total pressure control as you gently compress the meibomian glands.

PERSONALIZE IT

Select only the areas needing treatment.

A white handheld device with a digital display and a button. The display shows 'eyelid 41°C', 'melt time 08 sec', and 'LED 62 sec'. The device is shown against a light gray circular background.

eyelid 41°C
melt time 08 sec
LED 62 sec

HOW IT WORKS

RESULTS YOU CAN COUNT ON

In the pivotal clinical trial for iLUX®:

- Tear break up time, on average, improved 66% at two weeks and 74% at four weeks post-treatment, compared to baseline.⁵
- Meibomian gland scores, on average, increased more than three times at two weeks and nearly four times at four weeks post-treatment, compared to baseline.⁵
- Treatment in both eyes takes approximately 8-12 minutes.

iLUX



Insert the Inner Pad of the Smart Tip

- Instruct the patient to look up
 - Fully insert the Inner Pad behind the lower eyelid
 - Invert the iLUX® device to treat the upper eyelid
 - The patient may keep their eyes closed
-



Hold the Eyelid In Place

- Press the Compression Control Button
 - Apply just enough force to keep the eyelid from slipping out from the pads
 - Do not try to squeeze the eyelid
-



Begin Warming

- Slide the Heater Control Switch to activate the warming LEDs
 - Data from the Smart Tip precision sensors is sent to the display
 - Once the temperature reaches 38°C, the meibum begins to melt
 - There is a 90 second heating limit before the LEDs are disabled
-






Visualize the Meibum Expressing

- View the target glands through the magnifying lens
- Shift to Expression Mode by sliding back the Heater Control Switch
- Slowly increase compression, subject to patient comfort. Alternate with relaxation to effectively express the meibum
- The meibum may be clear, cloudy or inspissated
- If inspissated, additional heating/compression cycles may be required
- Once melted or clear meibum is expressed, treatment in this zone is complete

DEMONSTRATED EFFICACY WITH ILUX®

iLUX® was shown to be equivalent to LipiFlow† and produced statistically significant improvement in signs and symptoms of MGD vs. baseline.^{5,*}



*Based on a prospective, randomized, open-label, multi-center, bilateral treatment clinical trial in 142 subjects comparing changes in MGD and patient symptoms following treatment with iLUX® and LipiFlow devices.

†LipiFlow is a trademark of Johnson & Johnson Vision Care, Inc.



THE DRY EYE EXCELLENCE PROGRAM

DEEP™ by Alcon, is your partner in helping you successfully meet your practice goals. By providing the tools and know-how, we partner with you through five implementation phases to provide you best-in-class dry eye management.

The program is a core component of your iLUX® purchase, helping you reach and treat the patients that need it most.



SYSTANE® IS THE #1 DOCTOR RECOMMENDED ARTIFICIAL TEAR⁶

Through our range of SYSTANE® products, our dry eye care continues even after the patient leaves the practice.





TAKE CONTROL. PERSONALIZE TREATMENT. PERFORM WITH CONFIDENCE. VISUALIZE RESULTS.

IMPORTANT PRODUCT INFORMATION

Indication:

The iLUX® Device is indicated for the application of localized heat and pressure therapy in adult patients with chronic disease of the eyelids, including Meibomian Gland Dysfunction (MGD), also known as evaporative dry eye.

Contraindications:

Do NOT use the iLUX® Device in patients with the following conditions: Patients whose pupils have been pharmaceutically dilated; patients who have undergone ocular surgery within prior 12 months; patients with ocular injury or trauma, chemical burns, or limbal stem cell deficiency (within prior 3 months); patients with active ocular herpes zoster or simplex of eye or eyelid or a history of these within prior 3 months; patients with cicatricial lid margin disease; patients with active ocular infection, active ocular inflammation or history of chronic, recurrent ocular inflammation within prior 3 months; patients with an ocular surface abnormality that may compromise corneal integrity; patients with lid surface abnormalities that affect lid function in either eye; patients with aphakia; or patients with permanent makeup or tattoos on their eyelids.

Warnings and Precautions:

Federal law restricts this device to sale by or on the order of a licensed healthcare practitioner.

Use of the iLUX® device is NOT recommended in patients with the following conditions: moderate to severe allergic, vernal or giant papillary conjunctivitis; severe eyelid inflammation; systemic disease conditions that cause dry eye; in patients who are taking medications known to cause dryness; or patients with punctal plugs.

Potential Adverse Reactions:

Potential adverse effects may include eyelid/eye pain requiring discontinuation of the treatment procedure, eyelid irritation or inflammation, temporary reddening of the skin, ocular surface irritation or inflammation (e.g., corneal abrasion, conjunctive edema or conjunctival injection (hyperemia)), and ocular symptoms (e.g., burning, stinging, tearing, itching, discharge, redness, foreign body sensation, visual disturbance, sensitivity to light).

ATTENTION: PLEASE REFER TO THE USER MANUAL FOR A COMPLETE LIST OF CONTRAINDICATIONS, INSTRUCTIONS FOR USE, WARNINGS AND PRECAUTIONS FOR THE iLUX® DEVICE.

-
1. TFOS. What Is DEWS II. Available at http://www.tearfilm.org/dettreports-tfos_dew_ii_report/32_30/eng/. Accessed May 9, 2018.
 2. Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. *Cornea*. 2012;31:472-478.
 3. Schiffman RM, Walt JG, Jacobsen G, Doyle JJ, Lebovics G, Sumner W. Utility assessment among patients with dry eye disease. *Ophthalmology*. 2003;110(7):1412-1419.
 4. Alcon Data on File, 2018.
 5. Hardten DR, Schanzlin JD, Dishler JG, et al. Comparison of a Handheld Infrared Heating and Compression Device for Treatment of Meibomian Gland Dysfunction to a Thermal Pulsation Device. Presented at the Annual Meeting of the American Society of Cataract and Refractive Surgery (ASCRS); April 13-17, 2018; Washington, D.C.
 6. Alcon Data on File, 2018.